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The usefulness of peanut specific IgE levels for diagnosing peanut allergy has not been studied in primary and
secondary care where most cases of suspected peanut allergy are being evaluated. We aimed to determine the
relationship between peanut-specific IgE levels and clinical peanut allergy in peanut-sensitized children and how
this was influenced by eczema, asthma and clinical setting (primary or secondary care). We enrolled 280 children
(0–18 years) who tested positive for peanut-specific IgE (> 0.35 kU/L) requested by primary and secondary
physicians. We used predefined criteria to classify participants into three groups: peanut allergy, no peanut allergy,
or possible peanut allergy, based on responses to a validated questionnaire, a detailed food history, and results of
oral food challenges.
Fifty-two participants (18.6%) were classified as peanut allergy, 190 (67.9%) as no peanut allergy, and 38 (13.6%) as
possible peanut allergy. The association between peanut-specific IgE levels and peanut allergy was significant but
weak (OR 1.46 for a 10.0 kU/L increase in peanut-specific IgE, 95% CI 1.28-1.67). Eczema was the strongest risk factor
for peanut allergy (aOR 3.33, 95% CI 1.07-10.35), adjusted for demographic and clinical characteristics. Asthma was
not significantly related to peanut allergy (aOR 1.93, 95% CI 0.90-4.13). Peanut allergy was less likely in primary than
in secondary care participants (OR 0.46, 95% CI 0.25-0.86), at all levels of peanut-specific IgE.
The relationship between peanut-specific IgE and peanut allergy in children is weak, is strongly dependent on
eczema, and is weaker in primary compared to secondary care. This limits the usefulness of peanut-specific IgE
levels in the diagnosis of peanut allergy in children.
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Although the double-blind placebo-controlled food chal-
lenge (DBPCFC) is the gold standard for diagnosing pea-
nut allergy [1], its use in daily practice is limited because
it is time consuming, expensive, and not available in all
hospitals. In practice, the diagnosis of peanut allergy is
usually based on a suggestive clinical history, together
with evidence of allergic sensitization to whole peanut
allergen [2-4]. There are however no universally agreed
criteria for a suggestive clinical history. For example, are
both objective symptoms, such as urticaria or vomiting,* Correspondence: p.l.p.brand@isala.nl
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reproduction in any medium, provided the orand subjective ones, such as abdominal pain, mouth and
tongue tingling diagnostic; should symptoms always occur
reproducibly after each exposure and remain absent
without exposure to the allergen; and how close should
the temporal relationship between exposure and symptoms
be? The lack of uniformity of criteria for a suggestive
clinical history may lead to over-and underdiagnosis of
peanut allergy [4]. Parental suspicion of peanut allergy
in their child is unreliable, with parent-suspected peanut
allergy being much more common than peanut allergy
confirmed by DBPCFC [5].
High levels of peanut-specific IgE are taken to indicate
clinical allergy to peanut [6]. Unfortunately, the cut-off
levels of peanut-specific IgE above which >95% of chil-
dren are clinically allergic to peanut vary from 15 to 57
kU/l in different studies [6-9]. This is likely to resultal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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protocols. As peanut-specific IgE levels have only been
studied in general population samples or in tertiary care
food allergy centres, it’s unclear how useful they are in
predicting clinical peanut allergy in children seen in pri-
mary and secondary care, where most cases of suspected
peanut allergy are evaluated.
As peanut sensitization is strongly related to loss-of-
function variations in the filaggrin gene found in eczema
[10] and to asthma [11], the relationship between peanut
sensitization and peanut allergy may be confounded by
eczema and asthma. To our knowledge, this has never
been studied to date.
The purpose of this study was to determine the rela-
tionship between the level of peanut-specific IgE and
clinical peanut allergy in peanut-sensitized. Additionally,
we aimed to assess the confounding influence of eczema
and asthma, and of setting (primary or secondary care) on
this relationship.
Methods
Study population
The study population included all 427 children (aged 0–18
years) tested positive to peanut-specific IgE (> 0.35 kU/L) in
our laboratory between 2003 and 2010. In the Netherlands,
children with suspected allergies are first seen by general
practitioners (GPs), and can only be assessed by a paedia-
trician after referral by their GP. Paediatricians in the
Netherlands are hospital-based and provide secondary or
tertiary paediatric care. Specific IgE testing is the routine
method of allergy testing by GPs and paediatricians
in the Netherlands [12]. Our clinical laboratory is the
only laboratory performing specific IgE testing in the
catchment area of our hospital, both for hospital-based
medical specialists and for GPs. The ImmunoCap system
(Thermo Fisher, Uppsala, Sweden) was used for all specific
IgE assessments throughout the study period [9].
In 2011, all these 427 subjects were invited to participate
in the present study, which was approved by the hospital’s
ethical review board. Parents, and where appropriate par-
ticipants, provided written informed consent.
Clinical assessment of peanut allergy
All 427 participants and their parents were mailed a
validated questionnaire (Food Allergy Quality of Life
Questionnaire) [13] to obtain information on exposure
to peanut and symptoms associated with it. Children
who reported recent ingestion of peanut in the last
month without a reaction were considered to not have
peanut allergy. Children who reported a reaction on
exposure to peanuts were invited for a detailed food al-
lergy history. This consisted of a comprehensive review
of symptoms on exposure to foods containing peanut,
and about the occurrence of these symptoms withoutexposure to peanut. Based on previous work defining
positive food challenges [14] and diagnosing peanut
allergy by history [15], we used predefined specific history
criteria to define participants as having or not having
peanut allergy (Table 1).
Participants with reproducible objective symptoms
within a reasonable timeframe after each exposure to
peanut and no such symptoms during avoidance of pea-
nut were classified as having peanut allergy. Participants
without a history of anaphylaxis or severe asthma who
did not meet any of these criteria were encouraged to
reintroduce peanut into their diet. These patients were
followed up by telephone and clinic visits. If peanut was
reintroduced without symptoms, they were defined as
not having peanut allergy. Participants who developed
objective symptoms upon exposure at home were defined
as having peanut allergy. When peanut allergy could not
be confirmed or rejected using this approach, participants
were offered a DBPCFC (using validated recipes for
peanut hidden in cookies, as previously described [16])
in our clinic. Participants with an unclear history who
declined a DBPCFC were defined as having possible peanut
allergy. This clinical assessment of peanut allergy was
made without knowledge of participants’ level of peanut-
specific IgE.
Assessment of asthma
Asthma symptoms were recorded using the ISAAC ques-
tionnaire [17]. Children were defined as having asthma if
they had a doctor’s diagnosis of asthma ever, and had expe-
rienced an episode of wheeze or had used bronchodilators
or daily maintenance medication in the last 12 months.
Participants invited for a detailed food allergy history
completed the Dutch translation of the Asthma Control
Questionnaire (ACQ) [18], and participants aged 6 years
and older performed spirometry before and after inhalation
of 400 ug of salbutamol as previously described [19].
Well-controlled asthma was defined as ACQ <1.0 and
an FEV1 of ≥ 80% of predicted.
Assessment of eczema
Eczema was defined as a positive response to: has the
child ever been diagnosed with eczema by a doctor, and
has the child had an itchy skin condition and generally
dry skin with onset before the age of 2 years, with flexural
involvement? [20].
Statistical analysis
Data were analysed using SPSS19 for Windows. Due to
the skewed distributions even after logarithmic transform-
ation, peanut-specific IgE was analysed by non-parametric
methods (Mann–Whitney U test). Chi-squared tests were
used to determine the relation between peanut allergy and
clinical characteristics. Multiple logistic regression was used
Table 1 Criteria for diagnosis or exclusion of clinical peanut allergy [14]
Peanut allergy Reproducible, objective symptoms (vomiting, urticaria/angio-oedema, wheeze, anaphylaxis), within a plausible
timeframe after recent exposure to a relevant quantity of peanut; and never experiencing these symptoms
without eating peanut
Possible peanut allergy - No reported exposure to a relevant quantity of peanut
- Exclusively subjective symptoms
- Not clearly reproducible symptoms
No peanut allergy - Objective symptoms without a clear and consistent relationship to reported peanut exposure, or
- Reported recent exposure to to a relevant quantity of peanut without reproducible symptoms, and
- Another plausible cause for the patient’s symptoms
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levels of peanut-specific IgE, and to adjust this for potential
confounding by asthma, eczema and clinical setting.
Results
Of the 427 participants, 280 (65%) were assessed in the
study. Clinical characteristics of these participants are
presented in Table 2. There were no significant differ-
ences in age, gender, setting, and specific IgE levels be-
tween those who participated in the study assessment
and those who declined participation (Table 2). The median
(interquartile range [IQR]) duration between measurement
of peanut-specific IgE and clinical assessment of peanut
allergy was 4.3 (4.1-6.0) years.
Peanut allergy
The assessment of study participants is described in Figure 1.
A total of 52 participants (18.6%) were defined as havingTable 2 Characteristics of study population
Participants Range
(n=280)
n (%) / median
Male gender 183 (65.4)
Age at IgE measurement (years) 6.9 0.3-18.0
3.5-11.4
Age at study participation 11.4 2.5-24.1
7.7-16.0
Primary care 176 (62.9)
Level of peanut-specific IgE (kU/l) 2.35 0.4-100.
0.9-11.5
Level of total IgE (kU/L) 426 6-5000
151-102
Atopic disease in history 266 (95.0)
- Eczema 213 (76.9)
- Asthma 139 (49.6)
- Allergic rhinitis 179 (67.0)
Family history of allergic disease 205 (89.9)
P values represent results of chi squared tests for proportions and Mann–Whitney Upeanut allergy (15 on the basis of a positive DBPCFC before
the study, 14 on the basis of a positive DBPCFC during the
study, and 23 as per criteria in Table 1). Thirteen children
with peanut allergy (25.0%) reported symptoms in one organ
system (most commonly skin or gastrointestinal tract), and
22 (42.3%) had symptoms in two organ systems. Seventeen
children (32.7%) reported respiratory symptoms after
exposure to peanut indicating anaphylaxis. Peanut allergy
was excluded in 190 participants (67.9%). A total of 38
(13.6%) were defined as having possible peanut allergy on
the basis of the study criteria (Table 1).
Association between peanut-specific IgE and peanut allergy
Participants with peanut allergy had higher peanut-specific
IgE levels than those who did not have peanut allergy
(p<0.001, Table 3). There was large overlap though in
individual peanut-specific IgE levels between participants
with peanut allergy, possible peanut allergy, and no peanutIQR Non-participants Range IQR p-value
(n=147)
n (%) / median
89 (61.0) 0.370
6.5 0.5-18.0 0.876
3.3-12.2
11.6 2.0-24.7 0.501
8.0-16.9
93 (63.3) 0.934
0 2.95 0.4-100.0 0.716
0.9-9.7
414 17-4755 0.809
0 163-1061
test for comparison of medians.
Questionnaire
N= 280
No peanut allergy
N= 146 (52%)
Possible peanut allergy
N= 134 (48%)
Detailed history
No peanut allergy
N= 17 (6%)
Possible peanut allergy
N= 70 (25%)
Peanut allergy
N= 47 (17%) 
Challenge at home 
N=15 (5%)
Peanut allergy inconclusive 
N= 37 (13%)
No peanut allergy
N= 14 (5%)
Peanut allergy
N= 1 (0.4%)
DBPCFC
N= 18 (6%)
No peanut allergy
N= 13 (5%)
Doubtful result
N= 1 (0.4%)
Peanut allergy
N= 4 (1%)
Figure 1 Study flowchart and classification of participants.
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were excluded from further analyses of the association
between peanut-specific IgE and peanut allergy. The
likelihood of peanut allergy was 14% at the median level
of peanut-specific IgE (2.35 kU/L), and 50% at a peanut-
specific IgE level of 51.0 kU/L. The highest probabilityTable 3 Characteristics of children with and without peanut a
Peanut allergy
n=52
n (%) /
median (IQR)
Male sex 33 (63.5)
Age at IgE measurement (years) 5.8 (2.8-12.1)
Primary care 25 (48.0%)
Level of peanut-specific IgE (kU/l) 14.8 (1.9-88.5)
Level of total IgE (kU/L) 312 (112–1044)
History of atopic disease 49 (94.2)
- Eczema 46 (90.2)
- Asthma 32 (61.5)
- Allergic rhinitis 29 (58.0)
Family history of allergy 41 (93.2)
Good asthma control* 8 (72.7)
* ACQ < 1.0 and FEV1 > 80% predicted.
P values represent results of chi squared tests for proportions and Mann–Whitney Uof peanut allergy was 87% at the highest level of peanut-
specific IgE (>100 kU/l).
The highest likelihood ratio of a positive peanut-specific
IgE test for peanut allergy was 16.3 (sensitivity 42%, speci-
ficity 97%, positive predictive value [PPV] 79%, negative
predictive value [NPV] 86%) at a level of 30.0 kU/L [21].llergy
No peanut allergy p-value
n=190
n (%) /
median (IQR)
124 (65.3) 0.809
6.9 (3.8-11.4) 0.506
127 (66.7%) 0.013
1.4 (0.7-5.2) <0.001
553 (172–1138) 0.427
181 (95.3) 0.804
134 (70.5) 0.004
85 (44.7) 0.032
128 (70.7) 0.088
136 (88.3) 0.355
15 (75.0) 0.890
test for comparison of medians.
Figure 2 Level of peanut-specific IgE (sIgE) in children with
peanut allergy, no peanut allergy, and possible peanut allergy.
P values represent results of Mann–Whitney U tests.
Table 4 Predictors of clinical peanut allergy, examined
in univariate analyses and in multiple logistic regression
analysis
Variable Univariate
analysis
Multiple logistic
regression analysis
OR 95% CI OR 95% CI
Male gender 0.92 0.49-1.75 1.03 0.47-2.25
Age (years) 1.00 1.00-1.00 1.00 1.00-1.00
Peanut-specific IgE (10 kU/L) 1.46 1.28-1.67 1.45 1.27-1.66
Asthma 1.98 1.06-3.70 1.93 0.90-4.13
Eczema 3.20 1.30-7.93 3.33 1.07-10.35
Rhinitis 0.58 0.30-1.09 0.82 0.35-1.89
Primary care 0.46 0.25-0.86 0.59 0.30-1.16
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(sensitivity 96%, specificity 15%, PPV 24%, NPV 79%) at
0.6 kU/L. The relationship between peanut-specific IgE
levels and peanut allergy differed between primary and
secondary care participants, with higher probability of pea-
nut allergy at all levels of peanut-specific IgE (Figure 3).
Association of peanut allergy with demographic and
clinical characteristics
The relationship between peanut allergy and demographic
and clinical characteristics is presented in Table 4. Eczema
was strongly related to peanut allergy (odds ratio [OR] 3.20,
95% CI 1.30-7.93), and remained highly significant after ad-
justment for age, gender, other atopic diseases, setting, and
level of peanut-specific IgE in multiple logistic regressionSetting
Peanut specific IgE
Pr
ed
ic
te
d 
Pr
ob
ab
ili
ty
0.1 1 10 100
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Figure 3 Predicted probability of peanut allergy (logistic
regression model) at each given peanut-specific IgE level (sIgE).analysis (adjusted OR [aOR] 3.33, 95% CI 1.07-10.35). In
this multiple logistic regression model, eczema was a stron-
ger risk factor for peanut allergy than peanut-specific IgE
levels (aOR for a 10-kU/L rise 1.45, 95% CI 1.27-1.66).
Of all the 213 children with eczema, 46 (22%) had peanut
allergy, as compared to 6 (9%) of children without eczema
(p=0.009).
Asthma was more common in children with peanut
allergy in univariate analysis, but this difference was no
longer significant after adjustment for the other variables in
the multiple logistic regression model (Table 4). Most chil-
dren had well controlled asthma (95/139, 68%); there was
no association of asthma control to either peanut-specific
IgE (p=0.978) or peanut allergy (p=0.890). Children with
asthma were no more likely to have reported an ana-
phylactic reaction to peanut (13/32, 40.6%) than children
without asthma (4/20, 20%, p=0.242).
Children in primary care were less likely to have pea-
nut allergy (16%) than those in secondary care (30%)
(OR 0.46, 95% CI 0.25-0.86). This remained significant
after adjustment for age and gender (aOR 0.47, 95% CI
0.25-0.87), but became non significant after entering
presence of atopic diseases and peanut-specific IgE levels
into the model (Table 4).
Discussion
This study shows that the relationship between peanut-
specific IgE and peanut allergy is significantly and strongly
influenced by the presence of eczema, and differs between
children in primary and secondary care. Eczema was a
stronger risk factor for clinical peanut allergy than the
level of peanut-specific IgE (Table 4). Peanut allergy was
more likely in secondary than in primary care, at each
level of peanut-specific IgE.
In our study, the proportion of peanut sensitized
participants who were defined as having peanut al-
lergy was smaller (Figure 1), and the predictive value
of peanut-specific IgE levels for clinical peanut allergy
weaker (Figure 3) than in previous research, where
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at peanut-specific IgE cutoff levels between 13.0 kU/L
and 57 kU/L, respectively [6-9]. In our population, a pre-
dicted probability of 95% was not even achieved at the
highest level of peanut-specific IgE (>100 kU/L)as 3 of
the 13 children with this high sensitization level were
not peanut allergic. This variability in the predictive
value of peanut-specific IgE levels for clinical peanut
allergy is likely to be due to differences in study popu-
lations and definitions of peanut allergy. Our results
indicate that the usefulness of peanut-specific IgE levels
in diagnosing peanut allergy depends on the presence of
eczema and the healthcare setting.
To our knowledge, this is the first study to show that
the relationship between peanut-specific IgE and peanut
allergy is influenced by a history of eczema. Even after
adjustment for age, gender, presence of rhinitis and asthma,
and the degree of sensitization to peanut, participants
with a history of eczema were three times more likely
to have peanut allergy than children without eczema
(Table 4). Eczema has been identified as a significant risk
factor for peanut allergy [22], and the filaggrin mutations
often seen with eczema represent a significant risk factor
for IgE-mediated peanut allergy [10]. Results of longi-
tudinal population studies show that eczema precedes
peanut sensitization in the majority of patients [23]. These
observations suggest that epithelial barrier dysfunction
plays a major role in the development of peanut allergy,
and that the presence or a history of eczema is a strong
marker of this risk factor. We could not confirm the
association between asthma control and peanut allergy
observed previously [24]. Most previous studies used
peanut sensitization as the marker for peanut allergy.
We previously showed that peanut sensitization is strongly
associated with polysensitization [25]. We hypothesize,
therefore, that the association between poorly controlled
asthma and peanut allergy is largely explained by the
presence of polysensitization, including sensitization to
peanut. Our results suggest that clinical peanut allergy
is not associated with poorly controlled asthma. In most
clinical guidelines, the use of peanut-specific IgE is
recommended as a useful part of the diagnostic evaluation
of potential peanut allergy [1,2]. In our population, the
relationship between peanut-specific IgE and peanut
allergy was dependent on eczema, and there was large
overlap in peanut-specific IgE values between children with
and without peanut allergy (Figure 2). Our results support
the view of The Dutch College of General Practitioners
that peanut-specific IgE have limited value in the diagnostic
workup of peanut allergy [12].
The clinical history is key to the diagnosis of peanut
allergy [26]. The strict history criteria that we used (Table 1)
were derived from studies on the interpretation of DBPCFC
results. Application of these criteria may help clinicians toavoid excessive and unnecessary avoidance of peanut,
which contributes to improving quality of life [27]. We did
not observe any severe allergic reactions to reintroduction
of peanut into the child’s diet using this approach.
The main strengths of our study include the relatively
large number of participants who were investigated in pri-
mary and secondary care, a population that is under repre-
sented in studies. The main weaknesses include the low
participation rate and the time lag between peanut-specific
IgE assessment and clinical assessment. As the sample
studied was representative of the root population referred
to the laboratory for specific IgE testing, selection bias is
unlikely. The median time lag between the assessments of
peanut-specific IgE levels and of peanut allergy was more
than 4 years. Although peanut-specific IgE levels may have
changed during this time period, the available evidence sug-
gests that peanut peanut allergy and peanut sensitization in
children are usually persistent [28]. The 4-year time lag is
therefore unlikely to have had a major influence on our
results. An additional limitation of our study is that the
reason for specific IgE assessments (allergy screening or
specific testing for suspected peanut allergy) was not
recorded. This may have differed between primary and
secondary care. A final limitation is that we did not perform
component resolved diagnostics or DBPFCFCs for peanut
in all children in our cohort. This, however, reflects current
paediatric allergy practice [2].
In conclusion, this study shows that the relationship
between peanut-specific IgE and clinical peanut allergy
is strongly influenced by the presence of eczema, and
differs between primary and secondary care. This limits
the usefulness of peanut senistization in the diagnosis of
clinical peanut allergy in children.
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